The quest for patent rights has seen bioprospecting as a scientific and commercial research paradigm in which bioprospectors explore secluded locations around Cameroon in order to find ‗new drugs from exotic plants'. Bioprospectors derive genetic and biochemical materials that are both scientifically and commercially valuable, and they subsequently patent these materials abroad away from the original source to justify legal ownership through intellectual property law. An almost unprecedented amount of discussion has been stimulated on the merits and demerits of genetic engineering of crop plants and biodiversity exploitation and has divided both the public and scientific communities. The arguments for and against genetic engineering are invariably based on visions or missions of the new technology from widely different ethical perspectives. Fundamental issues of man's relationship with nature and theological matters are issues of concern. The genetic engineering of living cells, plants, animals and human beings has brought ethical concerns and issues to the conservation of biodiversity. Agricultural productivity depends in part on the availability of biodiversity for the development of improved cultivars.
Introduction
Imagine a wonder plant like Prunus Africana teeming with extraordinary chemical properties.
Like most living organisms in a diverse but fragile biosphere, it is native to Cameroon which is one of the many poor countries of our global south. New developments in science, biotechnology, and intellectual property rights (IPR) regimes have come together to fuel a turn to nature as a site for cosmetic, pharmaceutical and agricultural discovery work. In the early 1990s, this particular configuration of actors and regulatory regimes fuelled millennial claims about the possibilities inherent in such ‗pharmaceutical prospecting' and the potential for massive benefits that could be garnered from the genetic wealth of areas with a high concentration of biodiversity.
At the time, one of the most promising strategies employed to identify how this material and the attendant knowledge of its use could be collected and used was a practice called ‗bioprospecting'. The term is now generally used generically for any program that endeavors to collect genetic material and/ or the knowledge of its use, usually from areas with high concentrations of biodiversity.
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The increased demand for biodiversity on the one hand, is driven by factors as diverse as plant breeding, drug development, and ecosystem services, and, on the other hand, by decreasing supplies, caused by overpopulation and globalization and the ensuing habitat destruction and cultural homogenization.
2 Biological resources constitute the backbone of the African economy as well as the life-support system for most of Cameroon people, especially the marginalized rural communities. Many of these resources, such as timber and agricultural crops, are traded commercially, and others are used traditionally for crafts like basket weaving and carving, in addition, many of the species with medicinal properties are harvested by local communities and pharmaceutical multinationals alike.
Biodiversity prospecting continues to be the exploration, extraction, and screening of biological diversity and indigenous knowledge for commercially valuable genetic and biochemical resources. The growing number of bilateral bioprospecting agreements among which the vast majority of cases cannot be effectively monitored or enforced by source communities, countries, thereby amounting to biopiracy. 3 The International Convention on Biological Diversity (CBD) entered into force in December 1993. The Convention offers a multilateral facade for addressing conservation and sustainable use of biodiversity. Article 8(j) of CBD states that Member States shall ‗subject to its national legislation, respect, preserve and maintain knowledge, innovations and practices of indigenous and local communities embodying traditional lifestyles relevant for the conservation and sustainable use of biological diversity and promote their wider application with the approval and involvement of the holders of such knowledge, innovations and practices and encourage the equitable sharing of the benefits arising from the utilization of such knowledge, innovations and practices'. 4 Although, the Convention promotes bilateral deals (such as commercial contracts and other agreements for access to biodiversity) is without plans to guard against ethical issues for access to and development of biological diversity. The
Convention recognizes that States have sovereign rights over their natural resources and those terms and conditions for access to these materials are within the domain of national legislation.
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Cameroon among other African nations and communities are faced with a daunting task when trying to govern access to genetic resources or ensure equitable sharing of benefits.
The interaction of social, cultural, and economic factors in environmental and agricultural management is complex. In addition, the administrative regime of Cameroon endures a chronic shortage of financial and material resources. This is particularly challenging in the realm of genetic resources, which is simultaneously technical, legal, and policy-oriented, cutting across many disciplines. 6 The African Model Law on Local Communities Rights and other regional initiatives indicate that African nations increasingly recognise the practical, political, and legal benefits of developing common African positions and approaches regarding genetic resources.
These legal instruments and more are highlighted in this paper as I discuss the ethical dilemma in genetic engineering in Cameroon. Artemisia judaica -An immunosuppressant drug being developed by GlaxoSmithKline that comes from a compound found in a termite hill in Gambia.
-A treatment for HIV taken from mycobacteria discovered in mud samples from the Lango district of central Uganda.
-Infection-fighting drugs from amoebas in Mauritius and Venezuela.
-An anti-diarrhoea vaccine developed from Egyptian microbes.
-A slug barrier made from a Somalian species of myrrh. Prunus (such as felling of trees to maximise the quantity of bark harvested) and they sold the bark to middlemen at very low prices.
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Consequences of the development and deployment of transgenic drugs or crops, the risks, benefits, and impacts, which are referred to as ‗extrinsic' concerns by, are foremost in many discussions of the relative merits of the new technology. Obviously, these issues are inherently linked and any absolute division is artificial.
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Without the consent of society at large, genetic engineering crops or medicine will fail in the marketplace.
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Biotechnological Science has had an enormous impact on human life, and scientists have been regarded as trustworthy and ethically sound, and pharmaceutical research and its role in drugs production as being intrinsically good. This view has been altered somewhat by the ethical issues surrounding the exploitation of biological resources or genetic modification of these resources. Cameroon is a country of exceptionally high ethnic groups and biodiversity. A key resource for food, pharmaceutical, and agricultural products, it is this diversity which now endangers it.
Cameroon is losing huge benefits from biodiversity for lack of legal protection against biopiracy yet biodiversity is the fifth thematic area of World Summit on Sustainable Development Through subtle processes, the roots of scientific knowledge are being starved, even as they are being rapidly exploited and harvested for profits. There are other actors who are arguing that the scientific manipulation of our biological resources is logical claiming that there's no such thing as biopiracy at all. The proponents of this idea argue that most corporations are acting in accordance with existing international intellectual property law. 24 Intellectual Property Rights (IPRs) lead to the skewing of research whose targets is to maximise profit. As such molecular biology has become a major source of techniques for biotechnological inventions. We are on the verge of losing our ability to tell one plant from another, and of forgetting how the known species interact among themselves and with their environment based on overexploitation of these biological nature.
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Changes in once priorities from social needs to potential return on investment, which is the main criteria for commercially guided research, entire streams of knowledge and learning will be forgotten and become extinct. While these diverse fields might not be commercially profitable, they are socially necessary. Our societies are now facing ecological problems, we need epidemiology, ecology, and evolutionary and developmental biology. We need experts on particular taxonomy groups, such as microbes, insects, and plants, to respond to the crisis of biodiversity erosion. The moment we ignore the useful and the necessary, and concentrate only on the profitable, we are destroying the social conditions for the creation of intellectual diversity. 
Bioprospecting and biopiracy
Bioprospecting has recently been coined to describe the practice of collecting and screening plant and other biological material for commercial purposes, such as the development of new The complexity of nature is, therefore, an ideal avenue for the streamlined production of new products. Thus, corporations often seek to profit from the labor of indigenous groups, rather than perform their own research and development. It can be estimated that seventy-five percent of current plant-derived pharmaceuticals were initially synthesized using information obtained from indigenous peoples 30 . Given the nature of the global market, namely its relatively free market status aimed at maximizing profits, it is not surprising that corporations seek shortcuts in their efforts to produce new drugs, thereby reducing labour cost. However, the nature of such a business model inherently results in an exploitative system in which the indigenous peoples or local communities in biodiversity-rich southern hemisphere from whom the biological information is obtained are ultimately marginalized and cut out of the profit model.
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Corporations cannot be criticized for attempting to maximize profits; however, they can be scrutinized for not upholding ethical business practices when dealing with the indigenous peoples from whom many of their products are derived; current practices directly conflict with ethical standards of business. One argument against biopiracy lies in the practice of patenting biological and genetic materials obtained from indigenous peoples. In order to profit without fear of rival companies stealing a product, corporations must patent their findings. However, the concept of patenting biological processes is an inherent contradiction to the traditional meaning applied to patents. Patents are issued to protect -human inventions;‖ however, biological systems isolated from plants are inherently not -human inventions,‖ but rather human discoveries. 
National and International Policy Frameworks on Biopiracy
The legally binding language of CBD Article 15(7) 33 points to an inter-State benefit-sharing obligation, that is not expressly linked to specific access activities and that is to be implemented through the adoption of domestic measures on benefit-sharing. Fair and equitable benefitsharing, however, is not defined in the CBD other than by reference to the means for its realisation. The language of the third CBD objective seems to point to three such means, each underpinned by specific provisions of the Convention: appropriate access to genetic resources, appropriate transfer of relevant technologies, and including biotechnology. Under the CBD, prior informed consent is the standard for ensuring a fair and equitable access and benefit-sharing agreements (ABA). The source country providing access to genetic resources must know in advance what will be done with the resource, and what benefits will be shared.
Without such an understanding between the collector and the supplier, there could be no true meeting of the minds, and no fair agreement on benefit sharing. Benefits may include support for research and conservation, contributions of equipment and materials, assistance to indigenous and local communities, upfront fees, milestone payments, and royalties.
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The problem with current international policy framework efforts is that they try to address the causes of biodiversity loss in precisely the reverse order of their current relative significance focusing more attention on the primary cause of diversity loss in Paleolithic times namely overharvesting of large and endangered mammalian and avian life than on wide-scale habitat destruction, which was first set in motion by the rise of Neolithic agriculture and the spread of sedentary human settlements across much of the globe and is now the leading cause of biodiversity loss. This is seen with the rise in genetic engineering or technological innovations.
The in situ preservation of ecosystems remains the only effective way to save biodiversity, and the academic community has a singularly immense responsibility to educate the public on the importance of realigning environmental law with the scientific understanding of biodiversity loss, a task, that promises its own epiphanya more spiritually satisfying understanding of the biosphere at its fullest and most diverse. 
